MALDI-MS
Diagnostic Accuracy Study Of A MALDI-MS Biomarker Of Acute Kidney Injury After Femoral Fracture Surgery
One fifth of the 70,000 UK patients that break their hip annually suffer a loss of kidney function (AKI). AKI can lead to a longer hospital stay, dialysis, and even death. Routine tests detect kidney injury at a late stage when treatment is ineffective. We plan to perform a multicentre clinical evaluation of a new test that identifies AKI early with the aim of reducing the severity and harm of AKI after hip fracture.
Chief Investigator: Dr David Griffith
Number and location of participating sites (by region/ country): UK 2
EudraCT number: N/A
Funder: Chief Scientist Office Scotland
Start and End date
Grant: 1 September 2018 to 29 February 2020
Recruitment: TBC
Current Status: Awaiting publication
Trial Unblinding Information: N/A
Contact details:
ACCORD https://www.accord.scot/
Chief Investigator: Dr David M Griffith, Anaesthesia, Critical Care and Pain, The University of Edinburgh, David.M.Griffith@ed.ac.uk
Trial manager: N/A
Research nurse: N/A
ECTU involvement: Statistics